Of note, the observed dichotomy of IGFBP-3 expression and patients’ survival in various cancers may be attributed to other factors such as IGF-1/IGF-2 expression, IGFBP-3 polymorphism status, tumor suppressor p53 family status, tumor metabolic characteristics, and others. This evidence concerns the gene IGF1 and neoplasm.